Angiopoietin and Adverse Outcomes in Cardiac Surgery

Not Applicable

Recruiting

• Conditions: Acute Kidney Injury; Cardiac Surgery
• Interventions: Other: blood sample

• Registration Number: NCT05817929
• Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Brief Summary

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery.

The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-23
• Study First Submitted: 2023-03-23
• Study First Submitted QC: 2023-04-05
• Study First Posted: 2023-04-18
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-21
• Last Update Posted: 2025-05-25
• Primary Completion: 2026-04
• Study Completion: 2027-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• adult patient scheduled for cardiac surgery under cardiopulmonary bypass

Exclusion Criteria

• patient less than 18 years old,
• redo surgery,
• urgent surgery,
• endocarditis,
• aortic root repair surgery
• aortic dissection
• heart beating surgery,
• heart transplantation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
cardiac surgery	blood sample	-

Primary Outcome Measures

Name	Time	Method
correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event	28 days	major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event	28 days	major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

Secondary Outcome Measures

Name	Time	Method
Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months	3 months
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months	6 months
Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications	28 days
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months	3 months
Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months	12 months
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications	28 days
Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months	6 months
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months	12 months

Trial Locations

Locations (1)

CHU Amiens Picardie; 🇫🇷 Amiens, France